Targeting PRAME with IMC-F106C: Advancing Immunotherapy for Solid and Hematologic Tumors

The study focuses on the development of a new immunotherapy called ImmTAC molecules, which are designed to target specific peptides on the surface of tumor cells in various cancers. The research aims to characterize the expression of a protein called PRAME, found in both solid and blood cancers, and to test the efficacy of an ImmTAC molecule named IMC-F106C in eliminating tumor cells.

The methodology involved analyzing tumor samples to determine PRAME expression levels and assessing IMC-F106C's ability to activate T cells to target and kill tumor cells. The results showed that PRAME is highly expressed in several cancers, including lung, melanoma, ovarian, and triple-negative breast cancer. IMC-F106C was found to effectively redirect T cells to attack tumor cells expressing PRAME, with significant activity at low concentrations.

The conclusion suggests that IMC-F106C could be a promising immunotherapy for patients with tumors expressing PRAME, especially those with certain genetic markers. The findings were presented at the American Association for Cancer Research meeting in 2020.